Objective: Few studies have been conducted to investigate the influence of recombinant human erythropoietin (rhEPO) on the long-term prognosis of endstage renal disease (ESRD). Design: A retrospective cohort study. Setting: The largest regional hospital renowned for haemodialysis in northern Taiwan. Conclusions: We demonstrated a reduction in long-term mortality related to supplementation therapy with rhEPO, vitamin D 3 and Fe. The findings provide a justification for the administration of combined supplement therapy in patients undergoing haemodialysis.
As Taiwan has the greatest incidence of end-stage renal disease (ESRD) worldwide, it is imperative to assess long-term cumulative survival in patients undergoing haemodialysis, which is the mainstay of ESRD therapy in Taiwan (1) . Haemodialysis patients with chronic kidney disease often have insufficient red blood cell production, which leads to anaemia (2) (3) (4) . Fe must be administered by a parenteral route to restore Fe to levels sufficient to maintain erythropoiesis. Although the improvement of anaemia among haemodialysis patients with recombinant human erythropoietin (rhEPO) therapy has been reported (5) (6) (7) (8) (9) , few studies have been conducted to investigate the effect of rhEPO use on long-term survival. In addition, evidence has been lacking regarding long-term survival after combined administration of iron sucrose and rhEPO, as suggested in recent studies (7, 10) . Because factors affecting long-term cumulative survival are very heterogeneous, the best way to assess the effectiveness of rhEPO therapy is to use a prospective randomised controlled trial. However, ethical concerns and the logistics of follow-up preclude our doing this. To be efficient, the alternative is to examine a retrospective cohort of existing patients who are undergoing dialysis with or without rhEPO therapy, taking into account other confounding factors. The aim of the present study was to assess the effect of rhEPO, vitamin D 3 and/or Fe therapy on long-term survival among ESRD patients receiving haemodialysis.
Methods

Study design and subjects
This was a retrospective cohort study to investigate the effect of supplement therapy on long-term survival, based on historic medical records. We enrolled a historical cohort of 702 ESRD patients receiving haemodialysis who were admitted to Li Shin Hospital, one of the largest regional hospitals renowned for haemodialysis in northern Taiwan, between 1993 and 2002. The primary outcome of interest in the study was all-cause mortality, assessed by following the patients until 30 June 2004. A total of 344 deaths were ascertained. The average followup time was 3?84 (SD 3?08) years. The independent variable of interest was the administration of supplement therapy including rhEPO, vitamin D 3 and Fe, which were reported to be associated with anaemia in patients receiving dialysis (2) (3) (4) . Treatment protocol and supplement therapy All patients underwent haemodialysis at regular intervals three or occasionally two times weekly after admission to hospital. Haemodialysis was performed with a Fresenius 4008B dialyser, with F7, F8, F70S, F80S and F100S dialysate with bicarbonate, blood flow of 200-350 ml/min and an interval of 3?5-4?5 h between sessions. Patients underwent supplement therapy with rhEPO, vitamin D 3 and Fe, according to haematocrit, transferrin saturation, ferritin, intact parathyroid hormone, calcium and phosphate concentrations. Table 1 shows the protocol for supplement therapy with rhEPO, vitamin D 3 and Fe. Note that patients may receive combinations of these three agents.
Data collection
Data on demographic features (age, gender and education level) were recorded at the inception of dialysis. Details on treatment regarding haemodialysis (supplement, vascular access and vascular access blood flow) were retrospectively extracted from historical dialysis records. Aetiology of ESRD was retrieved from medical charts. The aetiology of ESRD was classified into four groups: (i) chronic glomerulonephritis (CGN); (ii) hypertension or type 2 diabetes mellitus (DM); (iii) renal failure of unknown aetiology; and (iv) other causes, including autosomal dominant polycystic kidney disease, obstructive uropathy, autoimmune disease, congenital renal diseases, herbal-induced nephropathy, gouty nephropathy and analgesic-induced nephropathy.
Statistical analysis
The Kaplan-Meier method was used to calculate the overall cumulative survival curves and the specific curves to determine whether to use supplement therapy. The proportional hazards regression model was further adapted to estimate adjusted hazard ratios (HR) regarding the effect of supplement therapy on mortality risk after controlling for age, education and aetiology. Table 2 shows the distribution of demographic features, aetiology of ESRD and the administration of rhEPO, vitamin D 3 and Fe. Patients receiving haemodialysis were equally divided according to gender but were predominantly aged $45 years and had relatively low levels of education. Regarding aetiology, renal failure of unknown aetiology accounted for 43 % of patients, followed by hypertension or DM, CGN and other causes. Approximately 61 % of patients were treated with rhEPO, 7 % with vitamin D 3 and 20 % with Fe. The overall rate of using any of these three agents was 62 %. Administration of rhEPO alone accounted for 38 %. Combined therapy using two or three agents accounted for 23 %, including 3?56 % with rhEPO 1 vitamin D 3 , 16?67 % with rhEPO 1 Fe and 3?13 % with all three. Case-fatality rates are also reported in Table 2 . Casefatality rate by age group showed a U-shaped pattern, with a 50 % fatality rate for those aged #20 years, declining to 20 % for those aged 20-44 years, and then increasing to 44 % for 45-64 years, 55 % for 64-75 years and 72 % for $75 years. Gender did not have a significant effect on the case-fatality rate. The lower the education level, the higher the case-fatality rate. Patients treated with rhEPO, vitamin D 3 or Fe had a lower case-fatality rate than those not treated. Case-fatality rates in those treated with combination therapy were not significantly different from those with rhEPO only.
Results
The cumulative survival rate among these patients at 1, 3, 5 and 10 years was 77.78 %, 64.27 %, 51.16 % and 40.34 %, respectively. The survival curves stratified by supplementation of rhEPO, vitamin D 3 and Fe are shown in Fig. 1(a) to 1(c) . The survival rate among patients with rhEPO supplementation was significantly better than among those without rhEPO (log-rank x 2 5 87?74, P , 0?0001). Similar findings of better survival were also noted for the patients administered vitamin D 3 (log-rank x 2 5 13?84, P 5 0?0002) and Fe (log-rank x 2 5 27?42, P , 0?0001). When taking combination with Fe or vitamin D 3 into account (Fig. 2) , those with rhEPO supplementation combined with vitamin D 3 or Fe had the best survival rate, followed by those with rhEPO only and then those with no rhEPO (log-rank x 2 5 94?56, P , 0?0001). 
Discussion
The present study demonstrated that supplement therapy with rhEPO, vitamin D 3 or Fe significantly reduced mortality by 60 %, after adjustment for age, education and aetiology, in patients undergoing haemodialysis. After stratification of different combinations of supplement therapy, we found that the largest benefit was for a combination of all three supplements, with a 79 % reduction in mortality. The combination of rhEPO with vitamin D 3 or Fe gave a 70 % mortality reduction. The sole use of rhEPO halved mortality. Kalantar-Zadeh et al. demonstrated that low baseline serum Fe led to increased mortality and hospitalisation in a prospective cohort study of 1283 haemodialysis patients (11) . Recent studies have suggested that a combination of Fe and rhEPO improves anaemia (5, (12) (13) (14) . However, these studies lacked evidence to show any long-term benefit in terms of reduced mortality. Our 10-year follow-up of 702 patients corroborated a long-term benefit in the reduction of mortality attributed to the use of rhEPO, alone or combined with vitamin D 3 or Fe. Combined therapy may confer an extra 30 % reduction in mortality in comparison with the use of rhEPO alone. The improvement in long-term survival may be attributed to the improvement in anaemia, which yields numerous additional benefits, including a significant decrease in left ventricular mass index and septal wall thickness and normalisation of increased cardiac output.
Concern has been raised as to whether Fe replenishment may have serious or even life-threatening drug-related adverse effects. However, recent studies have shown that Fe is safe in cases of Fe deficiency or when the maintenance of Fe stores is required (15) (16) (17) . The better survival rate demonstrated in our study suggests the relative safety of supplementation for patients treated with rhEPO alone or combined with vitamin D 3 or Fe, in comparison to patients without these supplements. However, no empirical data on adverse effects, such as anaphylactic reaction or hypersensitivity, have been reported.
It may be argued that the number of cases treated with rhEPO 1 vitamin D 3 and rhEPO 1 vitamin D 3 1 Fe is too small to draw conclusions. Indeed, the results from such a small number of patients should be interpreted with caution, and further studies are warranted. However, our results have presented a significant survival advantage for those treated with rhEPO 1 vitamin D 3 and rhEPO 1 vitamin D 3 1 Fe compared with those receiving no supplement. Tables 3 and 4 also show a significant improvement with 95 % confidence intervals not including 1. These results would lessen the concern regarding insufficient statistical power.
Another limitation of the present study is that it was not a randomised controlled trial. Instead, a retrospective cohort design was adopted. The use of such a design, widely used in occupational epidemiology, is not only efficient in collecting data, but also dispenses with unnecessary long-term follow-up. The weakness is that a significant and beneficial result from the study may be blurred by other unmeasured clinical correlates. However, we believe that, although other confounding factors may attenuate the results, it is unlikely that such factors would render them non-significant.
In conclusion, we demonstrated a long-term benefit in reducing mortality related to supplement therapy with rhEPO, vitamin D 3 and Fe. The findings provide a justification for the administration of combined supplement therapy in patients undergoing haemodialysis.
